2025 HCPCS code J9061
(Active) Effective Date: N/A Chemotherapy Drugs Feed
Injection, amivantamab-vmjw, 2 mg
Medical necessity is established by the patient's diagnosis of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, as detected by an FDA-approved test.
In simple words: This code covers 2 milligrams of Rybrevant (amivantamab-vmjw), a medicine given through a vein to treat a type of lung cancer called non-small cell lung cancer.
This code represents 2 mg of amivantamab-vmjw, a monoclonal antibody administered intravenously to treat non-small cell lung cancer (NSCLC).
Example 1: A patient with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, receives 1050 mg of amivantamab-vmjw intravenously., A patient weighing 90 kg with NSCLC and EGFR exon 20 insertion mutations receives 1400 mg of amivantamab-vmjw every two weeks following four weeks of weekly infusions., A patient with NSCLC and EGFR exon 20 insertion mutations experiences an infusion-related reaction and is premedicated with antihistamines, antipyretics, and glucocorticoids before receiving amivantamab-vmjw.
Documentation should include confirmation of the patient's diagnosis of NSCLC with EGFR exon 20 insertion mutations, prior treatment with platinum-based chemotherapy, and the dosage of amivantamab-vmjw administered.
** This code is for the drug only; administration may be reported separately. If a partial vial is discarded, modifier JW may be applicable.
- Specialties:Oncology, Pulmonary Medicine
- Place of Service:Inpatient Hospital, On Campus-Outpatient Hospital, Off Campus-Outpatient Hospital, Clinic